Why Is TG Therapeutics (TGTX) Down 5.7% Since Last Earnings Report?

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • 5 hours ago

TGTX Stock Up on Positive Phase I Data for Subcutaneous Briumvi

TG Therapeutics jumps 9.5% after phase I data show that subcutaneous Briumvi achieved over 60% bioavailability, sustained drug exposure, and was well tolerated.

Zacks Investment Research • Jun 4, 2026

TG Therapeutics: Phase 1 Results Of Subcutaneous Briumvi Are A De-Risking Event

TG Therapeutics, Inc.'s Phase 1 results of subcutaneous Briumvi are a major de-risking event for TG's most important clinical development program. SC Briumvi's bioavailability, safety, and tolerability support expectations of non-inferiority to IV Briumvi, with phase 3 topline data expected late 2026 or early 2027. IV Briumvi's sequential growth has improved, with 2026 U.S. sales guidance raised to $885–900 million and with potential for beat-and-raise trends to continue.

Seeking Alpha • Jun 4, 2026

TG Therapeutics Flashes An Early Buy Signal — What Drove The Bullish Jump

TG Therapeutics stock popped Wednesday after the biotech company said an under-the-skin shot of Briumvi appeared as safe as the IV.

Investors Business Daily • Jun 3, 2026

TG Therapeutics Stock Surges After Drug Trial Update

Shares of TG Therapeutics Inc (NASDAQ:TGTX) are climbing Wednesday afternoon following the release of early-stage clinical trial data for a new formulation of its multiple sclerosis drug, BRIUMVI. Here's what investors need to know.

Benzinga • Jun 3, 2026

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027

GlobeNewsWire • Jun 3, 2026

TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Goldman Sachs 47th Annual Healthcare Conference, being held at the Loews Miami Beach Hotel, in Miami Beach, Florida on June 8-10, 2026.

GlobeNewsWire • Jun 2, 2026

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no evidence of disease activity (NEDA-3) in treatment naïve patients supporting early use of high-efficacy therapy NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post-hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating BRIUMVI® (ublituximab-xiiy) in treatment-naïve adult patients with relapsing forms of multiple sclerosis (RMS).

GlobeNewsWire • Jun 1, 2026

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 2-4, 2026.

GlobeNewsWire • May 28, 2026

TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study

TG Therapeutics announces that Briumvi's late-stage ENHANCE study met its goal, supporting a potential single-infusion regimen for relapsing MS patients.

Zacks Investment Research • May 28, 2026